To improve the lives of patients impacted by pulmonary disease
through the discovery and development of scientific innovations.
Creating solutions for current and future unmet healthcare needs.
Dynamix Biotechnology Inc. - DBI is a rapidly emerging biotech company dedicated to the commercialization of a treatment for Sarcoidosis.
Currently focusing efforts on DB-602, an injectable peptide that in extensive studies conducted has shown a greater efficacy than current FDA approved treatments.
Technology developed by Dr Andrew Schally, a Noble Prize winning Endooncologist and Dr Mehdi MirSaeidi who is the Chief of Pulmonology division at the University of Florida (UF)
Chief Executive Officer
Chief Operating Officer
VP of Intellectual Property
Regulatory & Quality
Manufacturing & Design
Quality System Manager
Director of Business Development
Director of Marketing
Address: 2688 SW 36th Street Ft. Lauderdale, Florida 33312
Copyright © 2023 Dynamix Biotechnology - All Rights Reserved.